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OBJECTIVES This study was designed to determine whether blood thrombogenicity is related to chronic
glycemic control in type 2 diabetes mellitus (T2DM).
BACKGROUND Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of
arterial thrombotic complications. Whether increased blood thrombogenicity is associated
with glycemic control has not been properly tested.
METHODS Forty patients with T2DM with hemoglobin A1c (HbA1c) 7.5% were selected. Maintain-
ing their current hypoglycemic therapies, patients were randomized into a conservative (diet
modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic
regimen for three months. Blood thrombogenicity was measured at baseline and after three
months with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus
formation. The repeated measurements allowed every patient to be his/her own control.
RESULTS Patients in both groups (48% and 74% of the conservative and intensive groups, respectively)
improved glucose control (HbA1c reduction 0.5%), showing a significant decrease in blood
thrombogenicity. A significant positive correlation was observed between the reduction in
thrombus formation and the reduction in HbA1c (r  0.47, p  0.01). The reduction in
HbA1c achieved by both treatments was comparable. Patients without glycemic improvement
showed no change in blood thrombogenicity. Improved glycemic control was the only
significant predictor of a decrease in blood thrombogenicity.
CONCLUSIONS In T2DM, there is an association between improved glycemic control and blood thrombo-
genicity reduction. The effect of glycemic control on the thrombotic complications of T2DM
patients deserves further investigation. (J Am Coll Cardiol 2001;38:1307–12) © 2001 by the
American College of Cardiology
Type 2 diabetes mellitus (T2DM) is a major independent
risk factor for coronary artery disease. These patients show
not only accelerated atherosclerosis but increased morbidity
and mortality due to thrombotic complications of athero-
sclerosis (1,2) and following percutaneous coronary inter-
ventions (3). As this increased risk is only partially explained
by the association of T2DM with other classical risk factors
(4), additional contributions to the process of atherosclero-
sis, such as a hypercoagulable state, are considered likely to
play a role (5).
The procoagulant state associated with T2DM (6) is
clinically manifested by a high rate of acute arterial throm-
botic episodes. Most of the described procoagulant
features are more striking in poorly controlled patients.
Although there are a number of proposed mechanisms by
which hyperglycemia can induce thrombogenicity (5,7),
the evidence for reversibility after glycemic control is
not convincing (8–11). One possible explanation for this
discrepancy is that the hypercoagulable state is not ac-
curately assessed by measurements such as in vitro plate-
let aggregation or levels of coagulation or fibrinolytic pro-
teins, which may not reflect the entire process of arterial
thrombosis in vivo (12,13). Using an ex vivo model of
platelet-dependent thrombus formation under physio-
logically relevant shear stress, we have previously shown
that patients with T2DM have increased blood thrombo-
genicity when compared with a population of non-diabetic
subjects matched for the presence of other cardiovascular
risk factors (14).
Our hypothesis was that the observed increase in blood
thrombogenicity is partially mediated via chronic glycemic
control. To test that hypothesis we compared the effect
of a conservative versus an intensive approach of man-
aging diabetes on blood thrombogenicity of patients with
T2DM. We therefore designed a protocol in which
patients were randomized to continued conventional ther-
apy (conservative approach) or the addition of a thiazo-
lidinedione to their current therapy (intensive approach) for
three months.
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METHODS
Patient population. The study included 40 patients with
T2DM. Inclusion criteria were a history of diabetes of 1
year, age between 20 and 70 years, hemoglobin A1c
(HbA1c) levels 7.5% and current treatment with insulin
and/or a sulfonylurea. All subjects were instructed to per-
form and log finger-stick glucose measurements, and a
glucose-monitoring device (One-Touch Profile, Lifescan,
Milpitas, California) was supplied to every patient.
Exclusion criteria included a contraindication to the use
of thiazolidinediones, baseline transaminase levels 2 times
the upper normal limit, uncontrolled hypertension, lactating
or pregnant women, fasting C-peptide levels 0.1 ng/ml,
treatment with troglitazone or metformin in the prior three
months, a history of acute coronary syndrome or revascu-
larization in the past three months, malignant diseases,
hematologic disorders and concurrent anticoagulant or an-
tiplatelet therapy (other than aspirin).
Study design. Subjects maintained their current hypogly-
cemic therapy and were randomized (double blind) to
receive placebo or troglitazone 600 mg once a day for three
months. Patients returned for monthly visits during the next
three months for safety monitoring. Results of home glu-
cose monitoring were reviewed and adjustment of initial
antidiabetic therapy (insulin or SU) was made if necessary to
avoid hypoglycemia. All other drug therapy remained un-
changed during the study period. A reduction in HbA1c
0.5 was considered to be clinically significant. The Insti-
tutional Review Board of Mount Sinai Medical Center
approved the protocol and informed consent was obtained
from all subjects. Troglitazone and matching placebo tablets
were supplied by Parke-Davis (Morris Plains, New Jersey).
The following parameters were determined following an
overnight fast at baseline and after three months: lipid
profile, fibrinogen, blood cell count, glucose, routine bio-
chemical parameters, creatinine, HbA1c, urine analysis,
urine albumin/creatinine, total plasma insulin, C-peptide
level and C-reactive protein (CRP). HbA1c was measured
by ion-exchange high performance liquid chromatography
(Bio-Rad Variant, Hercules, California). C-reactive protein
was measured by a high-sensitivity assay (Dade Behring,
Germany).
Assessment of blood thrombogenicity. EX-VIVO PERFU-
SION CHAMBER. The effect of glycemic control on blood
thrombogenicity was assessed as the change in the thrombus
area formed in an ex vivo perfusion chamber (15) at baseline
and three months after randomization. The description,
validity and reliability of the Badimon perfusion chamber to
study blood thrombogenicity on defined substrates under
stable rheologic conditions have been previously reported
(15). Perfusion chamber experiments were performed in the
mornings, following an overnight fast.
The perfusion chamber consists of a cylindrical flow
channel (1  25 mm) that allows the blood to flow over the
thrombogenic substrate. Perfusions were performed for
5 min at a flow rate of 10 ml/min (shear rate: 1690/s;
Reynolds number 60; average velocity 21.2 cm/s), to mimic
the local rheology present in mildly stenotic coronary
arteries. In brief, a 19-gauge catheter was carefully inserted
into an antecubital vein. After 5 ml of blood was discarded,
the catheter was connected to the Badimon perfusion
chamber. Constant flow was maintained by a peristaltic
pump (Masterflex, Cole-Palmer Instruments, Vernon Hill,
Illinois) distal to the chamber. To mimic severe arterial
injury, surgically prepared porcine aortic tunica media was
used as thrombogenic substrate.
Histologic assessment of thrombus formation was per-
formed by histomorphometry as previously described (15).
In brief, the perfused segments were fixed in paraformalde-
hyde and six 2-mm cross sections (two in the proximal,
middle and distal thirds respectively) were removed and
paraffin embedded. Sections (5 m) were cut and stained
with Masson’s trichrome-elastin to visualize the total
thrombus formed on the substrates. Morphometric analysis
of the thrombus was conducted at 400 magnification and
thrombus area on each section was measured by computer-
assisted planimetry using ImagePro Plus software. Results
are given as the average of the analyzed sections, and the
results from the perfusion chamber were averaged to obtain
the overall thrombus formation per patient.
HEMATOLOGIC PARAMETERS. Citrated plasma samples,
obtained pre- and post-treatment, were kept at 70°C for
the analysis of plasminogen activator inhibitor 1 (PAI-1)
(American Diagnostics Inc., Greenwich, Connecticut), pro-
thrombin fragment F12 (Dade-Behring, Germany) and
sP-selectin (Boehringer-Mannheim, Germany). Assays
were performed following the manufacturer’s instructions.
DATA ANALYSIS. All evaluations were blind to the therapeu-
tic group. Data are given as mean standard error. Baseline
differences between the treatment groups were assessed
using non-paired Student t test or Mann-Whitney U test
when distribution was not normal. Repeated measures
analysis of variance (RM-ANOVA) was used to test the
effect of treatment on the HbA1c and thrombus formation-
dependent measures. Repeated measures analysis of variance
was also used to test treatment and/or glycemic improve-
ment effects, and greenhouse Geisser-adjusted Fs are re-
ported for these analyses. Post-hoc tests of the hypothesized
interaction (time  glycemic improvement group) were
conducted by testing the slopes of each improvement group
Abbreviations and Acronyms
ANOVA  analysis of variance
CRP  C-reactive protein
HbA1c  hemoglobin A1c
MANOVA  multivariate analysis of variance
PAI-1  plasminogen activator inhibitor 1
RM-ANOVA  repeated measures ANOVA
T2DM  type 2 diabetes mellitus
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by an unpaired Student t test. Repeated measures multivar-
iate analysis of variance (MANOVA) was conducted for all
other exploratory-dependent measures, and Wilk’s  values
are reported for these analyses. Subgroup analyses were
performed by RM-ANOVAs. Follow-up Pearson correla-
tions between delta scores were conducted. Finally, two-
tailed significance level was set at 0.05. Statistical analyses
were performed with SPSS 10.01.
RESULTS
Study population and baseline data. All patients com-
pleted the study without adverse events. Baseline thrombus
formation in the study population was comparable to
previous studies done in patients with a hypercoagulable
state (14) and was independent of insulin levels, fasting
C-peptide or treatment with insulin and/or sulfonylurea
(Table 1).
Comparison between treatment groups. Unpaired t tests
and non-parametric tests revealed no significant differences
in baseline characteristics between treatment groups (Table
2). Although the RM-ANOVA revealed a significant
value when the measured biological variables were tested,
examination of the interactions for each variable suggested
that the significant changes were not slope differences of
clinical relevance. Two planned RM-ANOVAs demon-
strated that the interaction between treatment group and
both HbA1c levels and thrombus formation were not
significant (F [1,38]  2.1, p  0.16; and F [1,34]  2.7,
p 0.10, respectively). These findings are not surprising, as
we were testing an intensive treatment against a conservative
treatment, and both are active treatments. In fact, 48% of
the conservative treated patients and 78% in the intense
group showed glycemic improvement (mean change 
0.05% and 0.1%, in the conservative and intensive
groups, respectively).
Effect of glycemic improvement on blood thrombogenic-
ity. Twenty-four patients (14 from the intensively treated
group and 10 from the conservatively treated group) showed
a reduction in baseline HbA1c 0.5% and a significant
reduction in mean HbA1c levels (9.2%  0.2% to 7.8% 
0.1% at baseline and three months respectively, p  0.01).
Unpaired t tests and non-parametric tests revealed no
significant differences in baseline characteristics of any of
the biological variables between glycemic improvement
groups.
A planned RM-ANOVA for thrombus formation with
only glycemic improvement as the between-subjects factor
demonstrated that the time  glycemic improvement inter-
action was highly significant (F [1,34]  8.6, p  0.01).
Including both treatment and glycemic improvement as
between-subject factors continued to reveal only a “time by
glycemic improvement” interaction (F [1,32]  5.8, p 
0.05). A t test of changes in thrombus formation across the
study revealed that patients with glycemic improvement had
significantly less thrombus formation compared with those
without improvement (mean change 3,373 2/mm vs.
1,126 2/mm; for improved versus non-improved respec-
tively, t [1,34]  2.9; p  0.01).
A repeated-measures MANOVA for the other biologic-
dependent measures in the whole study population (sP-
selectin, F12, CRP, lipid levels, fibrinogen, leukocyte
count and PAI-1) revealed that the Wilk’s  for the time by
improvement status by type of biological variable was not
significant (Wilk’s   0.82; F [4,27]  1.4, p  0.05).
However, there was one variable (sP-selectin) in which the
values of the improved group changed from clinically
elevated to not clinically elevated, so we chose to test this
one variable singly. We then conducted a RM-ANOVA on
this variable, and the time by glycemic improvement inter-
action (F [1,37]  4.8, p  0.05) was significant. Glyce-
Table 1. Baseline Patient Characteristics
Conservative Intensive Total
n 21 19 40
Male 11 13 24
Female 10 6 16
Age 57.0  1.7 57.2  1.8 57.1  1.2
BMI 31.5  2.1 30.4  1.9 31.0  1.4
Smokers 5 5 10
Fasting glucose (mg/dl) 171  11.9 160  12.9 165  8.7
HbA1c (%) 9.2  0.2 9.1  0.3 9.1  0.1
Total cholesterol (mg/dl) 198  8 190  8 194  5
LDL cholesterol (mg/dl) 121  6 122  6 121  4
HDL cholesterol (mg/dl) 45.5  2.6 45.7  2.4 45.6  1.7
ACE inhibitors 8 8 16
Statins 8 4 12
Aspirin 5 8 13
Insulin 7 9 16
Sulfonylurea 15 10 25
Baseline thrombus area 14,389  762 15,347  1,337 14,855  752
Thrombus area is expressed as m2 mm. There are no significant differences between groups.
ACE  angiotensin-converting enzyme; BMI  body mass index; HbA1c  hemoglobin A1c; HDL  high-density
lipoprotein; LDL  low-density lipoprotein.
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mically improved patients (X  45.3) had a significantly
larger decrease in P-selectin levels than did those who did
not improve (X  4.2; tn [1,37]  2.2, p  0.05).
In order to explore clinically significant changes in the
measured biological variables, subgroup analysis were per-
formed. RM-ANOVA in the subgroup of patients with
glycemic improvement in the conservative treatment group
revealed a significant reduction in body mass index and in
low-density lipoprotein cholesterol (p  0.05). sP-selectin
and CRP levels were also significantly reduced. The same
analysis in the subgroup of patients with glycemic improve-
ment in the intensive treatment group revealed significant
reductions in sP-selectin, CRP and glucose (Table 3).
A total of 16 patients (five in the intensive group and 11
in the conservative group) showed no improvement in
glycemic control and unchanged thrombus formation
(Table 3).
Effect of glycemic control improvement on blood thrombo-
genicity. A significant correlation was observed between
thrombus formation changes and HbA1c changes (r 0.47,
p  0.01), demonstrating that the more HbA1c was
reduced, the more thrombus formation was reduced. The
same interaction was not significant for sP-selectin.
DISCUSSION
Our study has demonstrated an association between glyce-
mic control improvement and blood thrombogenicity re-
duction in patients with poorly controlled T2DM. We
found that even placebo-treated patients who achieved a
reduction in HbA1c, presumably through better adherence
to diet and previously prescribed diabetic medications,
demonstrated a significant reduction in thrombogenicity.
Subjects without improvement in glucose control (from
either treatment group) failed to show improvement in
hypercoagulability. Both treatment groups included a sig-
nificant amount of patients with glycemic improvement
(48% and 74% in the conservative and intensive groups,
respectively), and there were no differences between treat-
ment groups in glycemic improvement or thrombus reduc-
tion. Glycemic improvement was the only independent
variable associated with reduction of thrombus formation.
In contrast to our findings, others have failed to show a
reduction in the hypercoagulable state of diabetic patients
after improving glycemic control (8–11). In these studies,
plasma markers of hypercoagulability and in vitro platelet
aggregometry were used to study the hypercoagulable state.
Platelet aggregometry assumes that fibrinogen binding to
glycoprotein IIb/IIIa is the only relevant interaction in
platelet function. However this may be true only in a stirred
platelet suspension used in aggregometry (low shear rate
conditions) and cannot be applied to platelet activation in
arterioles or arteries (12), where high shear-dependent
platelet activation is present. Our goal was to assess platelet-
dependent thrombosis in a population with a high incidence
of arterial thrombotic episodes. The ex vivo Badimon
perfusion chamber, using native non-anticoagulated blood,
triggers thrombus formation by exposing the blood to
collagen under high shear conditions that mimic those
present in a mildly stenotic coronary artery. We propose
that the effect of metabolic control may be more apparent in
this model of arterial thrombosis, which closely simulates in
vivo conditions following spontaneous or iatrogenic plaque
rupture.
Our study design resembles routine clinical practice, in
which the addition of an insulin sensitizer and/or dietary
modification may be used to treat patients with T2DM who
are inadequately controlled on insulin or sulfonylurea treat-
ment (16). The thiazolidinedione troglitazone was selected
because of its effect on glucose control in patients with
T2DM. The reported in vitro antiplatelet effects of trogli-
tazone (17) were not apparent in our model of blood
thrombogenicity.
Potential clinical significance. The hypercoagulable state
of patients with T2DM appears to be an important factor
contributing to the accelerated atherosclerosis and high rate
of arterial thrombotic complications described in these
patients (5). Although there is no direct evidence linking
improved glycemic control to reduction in macrovascular
disease in diabetes, several studies have shown a relationship
Table 2. Results in Both Treatment Groups
Placebo Troglitazone
Glucose (mg/dl)
Baseline 171  11.9 160  12.9
Three months 176  11 138  13
HbA1c (%)
Baseline 9.2  0.2 9.1  0.3
Three months 8.9  0.2 8.0  0.2
Thrombus area
Baseline 14,389  762 15,347  1,337
Three months 14,123  750 12,292  834
Fibrinogen (mg/dl)
Baseline 275.9  17 288  18
Three months 264.9  19 252.0  17
Cholesterol (mg/dl)
Baseline 198  8 190  8
Three months 180  6 188  9
LDL (mg/dl)
Baseline 121  6 122  6
Three months 108  6 119  7
HDL (mg/dl)
Baseline 45  2 45  2
Three months 43  2 47  2
C-peptide (ng/ml)
Baseline 2.6  0.3 1.9  0.2
Three months 3.0  0.3 1.8  0.2
Insulin (mcU/ml)
Baseline 24.5  4 17.5  3
Three months 21.3  3 12.7  2
PAI-1 (ng/ml)
Baseline 36.2  2.6 24.1  2.6
Three months 33.4  2.7 20.7  1.6
sP-selectin (ng/ml)
Baseline 171  14 140  16
Three months 132  10 132  11
HbA1c  hemoglobin A1c; HDL  high-density lipoprotein; LDL  low-density
lipoprotein; PAI-1  plasminogen activator inhibitor 1.
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between glycemic control and the risk of coronary artery
disease (18–21) and cardiovascular mortality (18). Lower
blood thrombogenicity in patients with better glycemic
control may have contributed to a reduction in cardiovas-
cular events in these patients. Although it was significant
only in a subgroup analysis, a reduction in CRP following
glycemic improvement supports a potential link between
glucose control and the progression of atherosclerosis.
The in-hospital and six-month mortality of diabetic
patients following myocardial infarction are twice those of
non-diabetic individuals (22). The Swedish Diabetes and
Insulin-Glucose Infusion in Acute Myocardial Infarction
(DIGAMI) (23) study showed a 30% reduction in mortality
at 12 months in those diabetic patients who were treated
with intensive insulin therapy after myocardial infarction.
Lower blood thrombogenicity as a consequence of lower
blood glucose levels may have contributed to reduction in
coronary reocclusion and re-infarction, which are leading
causes of both in hospital death and late mortality excess
(24).
Potential mechanisms of blood thrombogenicity reduc-
tion after glycemic control. Hyperglycemia accelerates the
formation of advanced glycation end products, which are
known to cause endothelial dysfunction and thus may be
linked to platelet activation in diabetes (25). Advanced
glycation end products induce tissue factor production in
human monocytes in vitro (7) and may enhance platelet
reactivity (25). Hyperglycemia-induced oxidative stress has
been reported to promote thrombin formation (26) and
platelet activation (27) in patients with diabetes. Our
observation that patients showing glycemic improvement
also had a significant reduction in sP-selectin levels reflects
a decrease in platelet activation in vivo (28) and is consistent
with the link between hyperglycemia and persistent platelet
activation described by Davi et al. (27). Thus, there are
established mechanistic links between hyperglycemia and
the prothrombotic state in diabetes.
Levels of fibrinogen, PAI-1 and F12 were within or
close to the normal range in most of our patients, despite
clearly increased thrombogenicity, and may explain why we
were unable to observe an association between these vari-
ables and thrombus formation.
Study limitations. We cannot rule out the possibility that
a non-glucose-mediated effect of troglitazone may have
contributed to the improvement in thrombogenicity. How-
ever, troglitazone-treated subjects who remained in poor
control (n  5) showed no reduction in thrombogenicity.
Furthermore, thrombus reduction among subjects with
improved HbA1c was similar in both treatment groups,
supporting the critical role of glucose control in reducing
blood thrombogenicity.
In conclusion, glycemic control improvement is associ-
ated with blood thrombogenicity reduction in patients with
poorly controlled T2DM. Adequate glycemic control, espe-
cially in the setting of acute coronary syndromes or percu-
taneous coronary interventions, may have significant clinicalTa
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benefit by reducing the increased thrombotic complications
that are characteristic of T2DM patients.
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